The agonising negative trend in monitoring of clinical trials.
about
Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsSafeguarding patients in clinical trials with high mortality ratesSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsData safety monitoring boards: legal and ethical considerations for research accountability.An opinion and practice survey on the structure and management of data and safety monitoring boards.Implementation of a data and safety monitoring program in a general clinical research center.Role of the Data and Safety Monitoring Committee (DSMC).Liability issues for data monitoring committee members.Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials.Current controversies in data monitoring for clinical trials.Futility approaches to interim monitoring by data monitoring committees.Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.Aggressive vs. conservative phototherapy for infants with extremely low birth weight.The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes studyCan we trust the results of trials that are stopped early?Monitoring for lack of benefit: a critical component of a randomized clinical trialUpdate in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular diseaseReview of draft FDA adaptive design guidance.Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.Stopping guidelines for an effectiveness trial: what should the protocol specify?Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.A quality analysis of clinical anaesthesia study protocols from the Chinese clinical trials registry according to the SPIRIT statement."You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study
P2860
Q21090716-32A3DF13-1B30-4C8C-B065-D05BB92A5563Q24614627-D51BD3AC-688A-4A23-8DD7-18D0C33FB4ECQ28186580-31F637E3-986D-4F63-9C07-31A8CC3BB67AQ28710019-F097A718-412E-4B20-9107-9C4674ECDEE5Q30449989-302DFF79-569E-40BB-96E3-C9E175057C92Q30452792-1916A2D3-1102-4429-AB93-8DAEBC9F8114Q30666458-1628A1E7-1118-4E7C-B495-D9DD31C74A55Q30731720-8E42AB3B-B6A9-40FF-8065-D97233CFB277Q31016883-5C940257-8820-40BF-97AA-82B70A345465Q31017562-6281E7EB-D025-4DBB-840D-CA4ED5CBFB68Q31085612-71B80C62-5D02-4B94-9685-B2A63EDDF6E6Q31085620-3052C6B0-411B-4EE0-A34C-4C368CD9D5D0Q31122463-1AB6ED19-2DE2-4197-8B96-9D86004832C6Q33650220-BA29D765-DA7E-420A-A016-71C7EAAE4EF3Q34399616-6B998845-548C-4BF9-B3CA-EFC1CBD5AE92Q36530313-08AC9ED6-18BE-463E-A638-3814B78386DDQ37104771-CC126CBE-F542-419C-9A57-4404FEEDFF5AQ37614854-50C9D10D-DD66-4BF4-9E0C-26B5D21221B7Q37807934-8E2C85B5-1550-4230-8EBA-8A0EAF4C8223Q38376753-5F5DCC7F-476E-4B77-BBFB-FFE1DAEC2DDBQ38955252-F0760F0D-8B86-436B-B1CC-FD58E9F7F9F1Q39772400-9351BFF1-EC65-4C30-A7E0-1356CE50A5EFQ40714213-798CD0C2-4378-4986-8262-53E1D9AAA885Q42771076-15521C0D-8674-4C07-AA7E-ECDC094B10EFQ42800368-0AB1BF21-D602-42E8-AA9D-EB984AE67BEFQ46075424-F27C3E5C-9748-45F5-B8AA-5D950F2F2616Q55080074-D3BD9AE1-E2FB-48C6-A502-58035FF085E6Q57174614-3EB47501-9CE8-498E-8450-2A7D85BA68E9
P2860
The agonising negative trend in monitoring of clinical trials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The agonising negative trend in monitoring of clinical trials.
@ast
The agonising negative trend in monitoring of clinical trials.
@en
type
label
The agonising negative trend in monitoring of clinical trials.
@ast
The agonising negative trend in monitoring of clinical trials.
@en
prefLabel
The agonising negative trend in monitoring of clinical trials.
@ast
The agonising negative trend in monitoring of clinical trials.
@en
P2093
P1433
P1476
The agonising negative trend in monitoring of clinical trials.
@en
P2093
D G Julian
D L DeMets
S J Pocock
P304
P356
10.1016/S0140-6736(99)03464-9
P407
P577
1999-12-01T00:00:00Z